| LQDA - Liquidia Corp Ordinary Shares (Healthcare: Biotechnology) | Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-07-11) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Liquidia Corp, formerly Liquidia Technologies Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |